Photo by lcma1028 from unsplash
METHODS: A model described by McCabe and colleagues is adapted to show the value of CMI. To populate the model, threshold cost and real-world incremental cost-effec5veness ra5o (ICER) data from… Click to show full abstract
METHODS: A model described by McCabe and colleagues is adapted to show the value of CMI. To populate the model, threshold cost and real-world incremental cost-effec5veness ra5o (ICER) data from the health technology assessments performed by NICE in the past year (November 2015-December 2016) were used as comparators. Data collected in a prospec5ve observa5onal study conducted by Caris demonstrated a survival benefit in patents treated in line with the CMI report. An ICER for CMI was calculated based on the demonstrated survival benefit and the clinical u5lity.
Journal Title: Value in Health
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!